MwanzoNVON • BMV
add
Novo Nordisk A/S
Bei iliyotangulia
$ 683.81
Bei za siku
$ 676.00 - $ 692.00
Bei za mwaka
$ 638.00 - $ 1,624.38
Thamani ya kampuni katika soko
128.86B USD
Wastani wa hisa zilizouzwa
elfu 10.33
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (DKK) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 79.14B | -7.63% |
Matumizi ya uendeshaji wa biashara | 29.73B | 12.96% |
Mapato halisi | 26.89B | -4.74% |
Kiwango cha faida halisi | 33.98 | 3.13% |
Mapato kwa kila hisa | 6.04 | -4.73% |
EBITDA | 36.66B | -23.44% |
Asilimia ya kodi ya mapato | 21.34% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (DKK) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 26.96B | 2.49% |
Jumla ya mali | 542.90B | 16.60% |
Jumla ya dhima | 348.86B | 8.29% |
Jumla ya hisa | 194.05B | — |
hisa zilizosalia | 4.44B | — |
Uwiano wa bei na thamani | 15.66 | — |
Faida inayotokana na mali | 16.70% | — |
Faida inayotokana mtaji | 29.56% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (DKK) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 26.89B | -4.74% |
Pesa kutokana na shughuli | 7.62B | -38.06% |
Pesa kutokana na uwekezaji | -42.81B | 53.07% |
Pesa kutokana na ufadhili | 29.47B | -20.00% |
Mabadiliko halisi ya pesa taslimu | -5.62B | 86.41% |
Mtiririko huru wa pesa | -34.95B | -1,011.09% |
Kuhusu
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
21 Des 1923
Makao Makuu
Tovuti
Wafanyakazi
69,150
